Clinical and Pharmacological Review on Novel Atypical Antipsychotic Drug: Paliperidone
Jagadeesh Panda¹ , P. Venkat Rao¹*, S. Mukunda Valli², T. Prabhakar³, S. Suneetha³¹Raghu College of Pharmacy, Dakamarri, Visakhapatnam.
²Yalamarty Pharmacy College , Tharluwada ,Visakhapatnam.
³A.U.College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.
Abstract: Paliperidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Chemically, it is the major metabolite of the widely used atypical antipsychotic drug, resperidone. Paliperidone is indicated for acute and maintenance treatment of schizophrenia. Paliperidone-ER (sold as INVEGA) is the first oral atypical antipsychotic with an extended release, which is achieved by osmotic-controlled release oral delivery system. Paliperidone is a centrally active dopamine Type 2 (D2) antagonist which is metabolized by dealkylation, hydroxylation, dehydrogenation and benzisoxazole scission.Paliperidone gradually rise to reach peak plasma concentration (Cmax ) approximately 24 hours after dosing. The maximum pharmacokinetics of paliperidone administration are dose-proportional within the recommended clinical dose range (3 to 12 mg).The terminal elimination half-life of paliperidone is approximately 23 hours
Keywords: Paliperidone; risperidone; antipsychotic; schizophrenia Back to TOC